Mantle Cell Lymphoma (MCL) Completed Phase 2 Trials for Bortezomib (DB00188)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00980395Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaTreatment
NCT00201877Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaTreatment
NCT00063713VELCADE in Subjects With Relapsed or Refractory Mantle Cell LymphomaTreatment
NCT00581776Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaTreatment
NCT00958256Study of Bortezomib in Combination With Cyclophosphamide and RituximabTreatment